Natural Product (NP) Details

General Information of the NP (ID: NP0953)
Name
Plasmin
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Lycium barbarum glycopeptide
SuperKingdom: Eukaryota
Kingdom: Plantae
Phylum: Tracheophyta
Class: Magnoliopsida
Order: Solanales
Family: Solanaceae
Genus: Lycium
Species: L. barbarum
Disease Chronic arterial occlusive disease [ICD-11: BD4Z] Phase 2 [1]
Investigative
ADMET Property
Absporption
Caco-2 Permeability
 -5.843
 
MDCK Permeability
 -5.166
 
PAMPA
 +++
 
HIA
 - - -
 
Distribution
VDss
 -0.018
 
PPB
 61.8%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 +
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 +
CYP3A4 inhibitor
 ++
CYP3A4 substrate
 +++
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - -
HLM Stability
 - -
 
Excretion
CLplasma
 2.912
 
T1/2
 0.805
Toxicity
DILI
 +++
 
Rat Oral Acute Toxicity
 - -
 
FDAMDD
 +
 
Respiratory
 -
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 +
 
Drug-induced Nephrotoxicity
 - -
 
Drug-induced Neurotoxicity
 - -
 
Hematotoxicity
 -
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
TTD Drug ID
D0L9XS
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Trimetazidine      Angina pectoris     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 Trimetazidine and plasmin combined with alprostadil can effectively treat lower extremity arteriosclerosis obliterans.
Target and Pathway
Target(s) Fibrin (FG)  Molecule Info  [3]
References
Reference 1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021318)
Reference 2 Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. Exp Ther Med. 2019 Jun;17(6):4554-4560.
Reference 3 ClinicalTrials.gov (NCT01014975) A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. U.S. National Institutes of Health.
 Download Picture         KEGG Link